NCT07416695 2026-02-18
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC
Shanghai Henlius Biotech
Phase 1 Not yet recruiting
Shanghai Henlius Biotech
Zai Lab (Hong Kong), Ltd.